Nutex Health Inc.

Background

On July 22, 2025, Blue Orca Capital published a report alleging, among other things, that Nutex’s share price has “surged” after it “began submitting the majority of its patient bills to the arbitration process for settling out-of-network medical bills . . . using an unidentified ‘third party IDR vendor.’” The report further states that the “mystery consultant” is HaloHD, which, according to multiple lawsuits, has “engag[ed] in a coordinated fraudulent scheme to steal millions of dollars from insurance companies on behalf of and in conjunction with its healthcare billing clients.”

On this news, Nutex’s stock price fell $11.18, or 10.1%, to close at $100.01 per share on July 22, 2025, thereby injuring investors.

Then, on August 14, 2025, Nutex announced it would delay filing its quarterly financial statements for the period ending June 30, 2025, due to “non-cash accounting adjustments related to the treatment of stock based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings.”

On this news shares fell $18.22, or 16.4%, to close at $92.91 on August 15, 2025, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (2) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (3) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (4) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (5) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (6) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (7) accordingly, Nutex’s business and/or financial prospects were overstated; and (8) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.